Gilead Sciences, Inc. (GILD) and partner Arcus Biosciences, Inc. (RCUS) announce new data from Cohort B of the ARC-9 study.ARC-9 is a phase Ib/II study evaluating the safety and efficacy of etrumadenant (E), a dual A2a/A2b adenosine receptor antagonist, plus anti-PD-1 antibody zimberelimab (Z), FOLFOX and bevacizumab (“EZFB”), in three cohorts of patients suffering from metastatic colorectal cancer (mCRC).Cohort B of ARC-9 randomized 112 patients with comparable baseline characteristics between two arms: EZ ...